A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy

NCT06220773 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

276

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension
Type 2 Diabetes Mellitus

Interventions

DRUG: BR1019A
DRUG: BR1019B
DRUG: BR1019C
DRUG: BR1019A-1
DRUG: BR1019B-1
DRUG: BR1019C-1

Sponsor

Boryung Pharmaceutical Co., Ltd